Table 1.
Overall Baseline Characteristics of All Patients (N = 101)
| Characteristic | No. of Patients | No. of Patients Analyzed for Each Characteristic |
|---|---|---|
| Gender | 101 | |
| Female | 49 (49%) | |
| Male | 52 (52%) | |
| Age, ya | 57 (15) | 101 |
| Tumor type | 101 | |
| Renal cell carcinoma | 22 (22%) | |
| Breast cancer | 19 (19%) | |
| Head and neck SCC | 9 (9%) | |
| Bladder cancer | 9 (9%) | |
| Pancreatic cancer | 6 (6%) | |
| Sarcoma | 5 (5%) | |
| Ovarian cancer | 4 (4%) | |
| Neuroendocrine tumor | 4 (4%) | |
| Lung SCC | 3 (3%) | |
| Prostate cancer | 3 (3%) | |
| Melanoma | 2 (2%) | |
| Others | 15 (15%) | |
| Race | 101 | |
| White | 75 (74%) | |
| Black | 11 (11%) | |
| Unknown | 15 (15%) | |
| Bone metastasis | 53 (53%) | 101 |
| Prior BP | 26 (26%) | 101 |
| High PTHrP | 63 (62%) | 101 |
| Baseline laboratory assessmentsa | ||
| Calcium (8.5-10.5 mg/dL) | 13.0 (1.46) | 101 |
| Albumin (3.8-5 g/dL) | 3.57 (0.59) | 101 |
| Albumin-corrected calcium, mg/dL | 13.4 (1.51) | 101 |
| 25(OH)D, ng/mL | 23.4 (15.4) | 94 |
| Calcitriol, 18-72 pg/mL | 61.4 (53.5) | 92 |
| PTH (12-65 pg/mL | 4.22 (2.86) | 101 |
| PTHrP, pg/mL | 36.9 (20.3) | 90 |
| Creatinine, 0.6-1.3 mg/dL | 1.05 (0.44) | 101 |
| Phosphorus, 2.5-4.2 mg/dL | 2.69 (0.90) | 94 |
| eGFR, mL/min/1.73 m2 | 78.1 (30.9) | 101 |
aValues reported as the mean (SD).
25(OH)D, 25-hydroxyvitamin D; BP, bisphosphonate; eGFR, estimated glomerular filtration rate; PTHrP, PTH-related peptide; SCC, squamous cell carcinoma.